Lane Pitts, MD
Family Medicine · Hattiesburg, MSNPI 1528176823
Payments from drug & device makers
Across 433 payments — averaging $14.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Pfizer$766
- Boehringer Ingelheim$564
- Novo Nordisk$513
- Lilly USA, LLC$508
- Tris Pharma Inc$433
- plus $2K from 25 others
What the payments were for
- Food & beverage$6,247100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 100 | $1,224 |
| Pfizer | 59 | $766 |
| Boehringer Ingelheim | 36 | $564 |
| Novo Nordisk | 40 | $513 |
| Lilly USA, LLC | 36 | $508 |
| Tris Pharma Inc | 25 | $433 |
| Amgen | 23 | $351 |
| Johnson & Johnson | 14 | $249 |
| Merck | 15 | $245 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $207 |
| Novartis | 8 | $137 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $127 |
| GSK | 8 | $116 |
| Teva Pharmaceuticals USA, Inc. | 6 | $101 |
| Abbott | 5 | $94 |
| Bayer | 5 | $92 |
| Genentech USA, Inc. | 5 | $76 |
| Sanofi-aventis U.S. LLC | 4 | $62 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $58 |
| Phathom Pharmaceuticals, Inc. | 4 | $58 |
| AstraZeneca | 3 | $46 |
| Shire North American Group Inc | 2 | $31 |
| Dynavax Technologies Corporation | 2 | $31 |
| Amarin Pharma, Inc. | 2 | $29 |
| Amneal Pharmaceuticals LLC | 2 | $29 |
| Exact Sciences | 1 | $20 |
| Medtronic | 1 | $19 |
| IBSA Pharma Inc. | 1 | $18 |
| Shionogi Inc | 1 | $15 |
| Stryker | 1 | $15 |
| Inspire Medical Systems, Inc. | 1 | $13 |
How this compares
$6,247 in reported general payments places this provider in the 85th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 108 | $104,713 |
| MounjaroTirzepatide | 71 | $96,112 |
| OzempicSemaglutide | 90 | $95,475 |
| EliquisApixaban | 43 | $45,640 |
| XareltoRivaroxaban | 34 | $40,064 |
| SynjardyEmpagliflozin/Metformin Hcl | 19 | $19,851 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,762 |
| Rosuvastatin Calcium | 361 | $6,126 |
| Atorvastatin Calcium | 615 | $5,711 |
| SynthroidLevothyroxine Sodium | 79 | $5,320 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 296 | $4,263 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $4,139 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 15 | $3,931 |
| Losartan Potassium | 333 | $3,835 |
| Pantoprazole Sodium | 301 | $3,833 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy | $564 | $124,565127 claims |
| Lilly USA, LLCMounjaro | $508 | $96,11271 claims |
| Novo NordiskOzempic | $513 | $95,47590 claims |
| PfizerEliquis | $766 | $45,64043 claims |
| Johnson & JohnsonXarelto | $249 | $40,06434 claims |
| GSKTrelegy Ellipta | $116 | $7,76212 claims |
| AbbVieSynthroid | $1,224 | $5,32079 claims |
| AstraZenecaSymbicort | $46 | $4,13912 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $29 | $2,259220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Hattiesburg
- Rambod RouhbakhshHattiesburg$6M
- Omolara OtaigbeHattiesburg$17K
- Deborah CopelandHattiesburg$13K
- J DumasHattiesburg$12K
- Anny EvansHattiesburg$10K
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.